Camila Rojas

Hola, soy Camila Rojas, periodista apasionada por contar historias que conectan con las personas. Trabajo en diversos medios digitales, como No Cure Magazine, donde me especializo en temas de actualidad, cultura, tecnología y tendencias emergentes. Mi misión es crear contenido que no solo informe, sino que también inspire y genere impacto.
1593 Posts
Blood Clotting Risk Doubles With Erythritol Consumption: Insights From Pilot Study

Blood Clotting Risk Doubles With Erythritol Consumption: Insights From Pilot Study

A recent pilot study found that drinking a beverage containing erythritol (an artificial sweetener used to boost the content of stevia and monk fruit and to sweeten low-carb ketogenic products) more than doubled the risk of blood clots in 10 healthy individuals. Blood clots can break off from blood vessels and travel to the heart, triggering a heart attack, or the brain, causing a stroke. Previous research has linked erythritol to an increased risk of stroke, heart attack, and death. Dr. Stanley Hazen, lead author of the study and director of the Cardiovascular Diagnostic and Prevention Center at the Cleveland…
Leer más
Adani Group Faces Fresh Turbulence Amid Regulatory Conflict

Adani Group Faces Fresh Turbulence Amid Regulatory Conflict

Adani Group is under fire again, with its shares seeing significant volatility following fresh accusations from short-selling firm Hindenburg Research. Hindenburg’s latest report accuses the chairman of India’s Securities and Exchange Board of India (SEBI) of potential conflicts of interest, casting doubt on the regulator’s impartiality in its investigation into the conglomerate. The allegations have reignited concerns about corporate governance and financial transparency at Adani Group. Although the group's share prices initially fell, they managed to recover some of their losses by the end of the trading day. However, the ongoing saga highlights the fragile investor sentiment surrounding the Adani…
Leer más
Team USA’s Golden Dilemma: Balancing Legends and the Next Generation

Team USA’s Golden Dilemma: Balancing Legends and the Next Generation

The 2024 Paris Olympics saw the United States reclaim the gold medal in men's basketball, but the victory was not without controversy. The decision to limit Jayson Tatum's playing time sparked debate and raised questions about the team's strategy. As the United States looks ahead to the 2028 Los Angeles Games, the challenge of balancing established superstars with emerging talent will be paramount. While legends like LeBron James and Stephen Curry have dominated the international scene, the next generation of players, including Tatum, Anthony Edwards and Jalen Green, are eager to make their mark. The delicate balance between experience and…
Leer más
Meta modifies oversight of Trump’s social media profiles

Meta modifies oversight of Trump’s social media profiles

Meta is set to change some restrictions previously imposed on the Facebook and Instagram profiles of Donald Trump, the former president of the United States. Initially, in response to his comments praising the actions of those involved in the Capitol riot on January 6, 2021, Meta suspended Trump’s social media accounts indefinitely. However, in early 2023, these platforms reinstated his accounts with a promise to closely monitor any further infractions that could lead to additional suspensions lasting anywhere from a month to two years. As Trump actively campaigns against current US President Joe Biden, aiming to return to the presidency,…
Leer más
Eli Lilly’s Profits Skyrocket on Success of Mounjaro and Zepbound

Eli Lilly’s Profits Skyrocket on Success of Mounjaro and Zepbound

Pharmaceutical giant Eli Lilly delivered a stellar second-quarter performance, beating analysts’ expectations and raising its full-year outlook by a whopping $3 billion. The company’s flagship diabetes drug, Mounjaro, and its weight-loss counterpart, Zepbound, were the main drivers of the stellar growth. Mounjaro and Zepbound, both incretin drugs, have seen unprecedented demand, leading to supply constraints that Eli Lilly is aggressively addressing. The company has invested heavily in expanding manufacturing capacity, resulting in a 50% increase in production of these drugs in the second half of 2024 versus the prior year. Despite supply challenges, Eli Lilly’s revenues increased 36% year-over-year to…
Leer más